Skip to main content

Advertisement

Table 2 Distribution of new bone formation and fibrosis grades in the study groups at study intervals

From: Effect of the plant-based hemostatic agent Ankaferd Blood Stopper® on the biocompatibility of mineral trioxide aggregate

Histologic events Study groups Intensity of reaction Experimental periods
7 days 30 days 60 days 90 days
New Bone Formation MTA (%) Severe 0 30 70 100
Moderate 70 70 30 0
Mild 30 0 0 0
None 0 0 0 0
MTA-ABS (%) Severe 0 20 60 100
Moderate 60 80 40 0
Mild 40 0 0 0
None 0 0 0 0
Control (%) Severe 0 50 25 100
Moderate 12.5 37.5 75 0
Mild 87.5 12.5 0 0
None 0 0 0 0
Fibrosis MTA (%) Severe 0 0 0 0
Moderate 0 0 0 0
Mild 100 70 10 20
None 0 0 0 0
MTA-ABS (%) Severe 0 0 0 0
Moderate 40 0 10 0
Mild 60 40 0 50
None 0 0 0 0
Control (%) Severe 0 0 0 0
Moderate 25 0 0 0
Mild 75 37.5 25 75
None 0 0 0 0
  1. MTA Mineral trioxide aggregate, ABS Ankaferd blood stopper